Find out how emerging biotechs are unifying clinical, regulatory, and quality systems, and bringing submissions publishing in-house to accelerate their path to FDA and EMA milestones.
Aravax announces positive topline results in children from its Phase 2 clinical trial involving its lead product, PVX108 for the treatment of peanut allergy.
We sat down with Charlotte Egan, Sales Manager, Instrumentation and Applications at Miltenyi Biotec, to discuss her time mentoring as part of BIA's Women in Biotech initiative.
Levicept presented new data from its 518-patient Phase II trial of LEVI-04 at the American College of Rheumatology's annual meeting, ACR Convergence 2026.
Coulter Partners, the global expert building leadership teams for Health, Science, and Technology innovation businesses, successfully led a search assignment for MitoRx Therapeutics (“MitoRx”) and is pleased to announce the placement of Neil Anderson, Ph.D., as Chief Business Officer.
Oyster Therapeutics, formerly Kesmalea Therapeutics, has raised $60 million in Series A financing to advance a new generation of targeted protein degraders for neurodegenerative diseases. The financing will support the company’s lead oral, brain-penetrant tau degrader toward clinical development and further advance its proprietary SELFTAC® platform.
This member-only webinar explores how life sciences organisations can strengthen digital and AI capabilities, access training and funding opportunities, and prepare their workforces for the future.
Discovery Park, Kent’s science and innovation hub, has launched the eighth edition of its Discovery Spark accelerator programme, welcoming 10 startups to its campus in Sandwich.
Pioneer Group – the company leading the regeneration of the Grafton Centre – has announced Cambridge-based Envision Health as the winner of its first accelerator programme, aimed at supporting the city’s early-stage tech companies.
As Most Favoured Nation (MFN) drug pricing policies increase uncertainty around future drug revenues, early-stage biotech companies face greater scrutiny from investors and potential partners.
Like the small sweets children will be collecting this weekend, John Healey’s first Budget brought initial excitement, but was followed by mild disappointment.
